首页> 外文期刊>Journal Of Cutaneous Immunology and Allergy >T helper type 2 signatures in atopic dermatitis
【24h】

T helper type 2 signatures in atopic dermatitis

机译:特应性皮炎的T辅助2型标志

获取原文
           

摘要

T helper type 2 (Th2)‐derived cytokines, such as IL‐4, IL‐13, and IL‐31, play a fundamental role in the development and progression of atopic dermatitis (AD). In addition to gene mutations of filaggrin (FLG), the Th2‐deviated microenvironment downregulates FLG expression and disrupts barrier function, resulting in Staphylococcus aureus colonization and increased penetration of external allergens. From lesional AD skin, the Th2 milieu helps to release Th2‐related chemokines such as CCL17, CCL22, and CCL26, which augment recruitment of Th2 cells and eosinophils. IL‐4 and IL‐13 stimulate B cells to produce IgE that links AD to other atopic comorbidities. IL‐31 is the major pruritogenic cytokine in AD. Notably, the anti–IL‐4 receptor α antibody dupilumab and the anti–IL‐31 receptor A antibody nemolizumab have proven to be effective for treatment of AD. In the present review, Th2 signatures in AD are examined and overviewed.
机译:T型辅助2型(Th2)衍生的细胞因子,例如IL-4,IL-13和IL-31,在特应性皮炎(AD)的发生和发展中起着基本作用。除丝蛋白(FLG)的基因突变外,Th2偏离的微环境还下调FLG表达并破坏屏障功能,导致金黄色葡萄球菌定植并增加外部过敏原的渗透。 Th2环境可从受损的AD皮肤释放与Th2相关的趋化因子,如CCL17,CCL22和CCL26,从而增加Th2细胞和嗜酸性粒细胞的募集。 IL-4和IL-13刺激B细胞产生将AD与其他特应性合并症关联的IgE。 IL-31是AD中主要的致敏细胞因子。值得注意的是,抗IL-4受体α抗体dupilumab和抗IL-31受体A抗体nemolizumab已被证明可有效治疗AD。在本综述中,将检查和概述AD中的Th2签名。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号